Overview and Scope
Biologics outsourcing refers to pharmaceutical companies partnering with external vendors or contract manufacturing organizations (CMOs) to outsource various aspects of biologic drug development, manufacturing, and supply chain management. This is used in the pharmaceutical industry for different purposes related to biological drug development, manufacturing, and supply chain management.
Sizing and Forecast
The biologics outsourcing market size has grown rapidly in recent years. It will grow from $17.74 billion in 2023 to $20.33 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing r&d costs, regulatory pressure, demand for specialized expertise, globalization.
The biologics outsourcing market size is expected to see rapid growth in the next few years. It will grow to $33.29 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to emerging markets' growth, personalized medicine, strategic alliances, biological drug patent expirations. Major trends in the forecast period include advancements in technology, increased outsourcing complexity, biosimilars market expansion, data analytics integration, supply chain resilience.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report
Segmentation & Regional Insights
The biologics outsourcing market covered in this report is segmented -
1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products
2) By Source: Human, Microbial, Other Source
3) By Application: Oncology, Cellular and Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications
4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization(CDMO)
North America was the largest region in the biologics outsourcing market in 2023. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12573&type=smp
Major Driver Impacting Market Growth
The rising number of cancer cases is expected to propel the growth of the biologics outsourcing market going forward. Cancer is a broad category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Biologics outsourcing plays a significant role in cancer cases by providing specialized expertise, resources, and infrastructure for the development, manufacturing, and clinical supply of biologic therapies, including monoclonal antibodies, immunotherapies, and other targeted biologics that are used for the diagnosis, treatment, and management of various types of cancer. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, there were 1,958,310 new cancer cases in the United States, and 609,820 cancer deaths are projected to occur in 2023. Further, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million by 2040. Therefore, the rising number of cancer cases is driving the growth of the biologics outsourcing market.
Key Industry Players
Major companies operating in the biologics outsourcing market report are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.
The biologics outsourcing market report table of contents includes:
1. Executive Summary
2. Biologics Outsourcing Market Characteristics
3. Biologics Outsourcing Market Trends And Strategies
4. Biologics Outsourcing Market - Macro Economic Scenario
5. Global Biologics Outsourcing Market Size and Growth
.
.
.
31. Biologics Outsourcing Market Other Major And Innovative Companies
32. Global Biologics Outsourcing Market Competitive Benchmarking
33. Global Biologics Outsourcing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Biologics Outsourcing Market
35. Biologics Outsourcing Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
